SSA
NPCE icon

Schonfeld Strategic Advisors’s Neuropace NPCE Stock Holding History

Schonfeld Strategic Advisors’s Portfolio NPCE Stock Details NPCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-14,426
Closed -$190K – 2444
2024
Q1 		$190K Buy
+14,426
New +$206K ﹤0.01% 1779

Other funds holding NPCE

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
KLC
Kent Lake Capital Reno, Nevada $222M AUM 18.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Schonfeld Strategic Advisors's NPCE Position: Q2 2024 in Review

Schonfeld Strategic Advisors sold out of Neuropace (NPCE) in Q2 2024, closing a stake of 14,426 shares — an estimated $190K sold.

Schonfeld Strategic Advisors first reported a position in NPCE in Q1 2024 and held it in 1 quarter. The position peaked at $190K in Q1 2024. 51 funds tracked by Wall St. Rank hold NPCE as of Q2 2024.

  • Schonfeld Strategic Advisors reported no remaining Neuropace position as of Q2 2024 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 14,426 Neuropace shares in Q2 2024, an estimated $190K.
  • Schonfeld Strategic Advisors first reported a position in Neuropace in Q1 2024 and held it in 1 quarter.
  • Schonfeld Strategic Advisors's Neuropace position peaked at $190K in Q1 2024.
  • 51 funds tracked by Wall St. Rank held Neuropace as of Q2 2024.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2024, filed 14 Aug 2024.